Certara names Christopher Bouton as chief technology officer

RADNOR, Pa. - Certara, Inc. (NASDAQ:CERT), a provider of biosimulation software for drug development with a market capitalization of $1.6 billion and annual revenue of $394.5 million, announced Thursday the appointment of Christopher Bouton as Chief Technology Officer. According to InvestingPro analysis, the company maintains a strong financial health score and shows promising growth potential, with net income expected to grow this year.

Bouton will lead the company’s technology strategy and development of an integrated model-informed drug development platform that incorporates generative AI and biosimulation technology. The company’s innovative approach has contributed to its solid gross profit margin of 60%, as reported by InvestingPro.

Prior to this appointment, Bouton founded and led Vyasa Analytics, which was acquired by Certara in 2022. At Certara, he has already overseen the development of AI-based products including CoAuthor, a generative AI tool for regulatory and medical writing.

"Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development," said William F. Feehery, Chief Executive Officer, according to the company’s press release.

Bouton’s previous experience includes founding Entagen, an enterprise analytics software provider that was later acquired by Thomson Reuters, and working as a computational biologist at Pfizer.

Certara’s platform combines scientific expertise with AI approaches to improve efficiency in therapeutic development. The company serves more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

The company states its biosimulation technology aims to accelerate drug discovery and development timelines while reducing costs. While the stock has experienced a recent 11% decline over the past week, InvestingPro analysis suggests the company is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.

In other recent news, Certara Inc. reported strong financial results for the first quarter of 2025, exceeding analyst expectations. The company achieved a revenue of $106 million, marking a 10% year-over-year increase and surpassing the projected $104.84 million. Certara’s earnings per share (EPS) came in at $0.14, beating the forecasted $0.11. The company’s adjusted EBITDA was $34.8 million, a 20% increase compared to the previous year, and above both analyst and consensus estimates.

In analyst updates, Barclays upgraded Certara’s stock rating from Equal Weight to Overweight and increased the price target to $14.00, citing the company’s strong performance and positive market positioning. Meanwhile, Morgan Stanley initiated coverage with an Equalweight rating and a $16.00 price target. Additionally, Certara held its annual stockholders meeting, where four Class II directors were elected, and the company’s independent auditor for fiscal year 2025 was ratified. These developments reflect Certara’s ongoing strategic and financial progress in the industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.